Drug Information

Drug General Information
Drug ID
D02ALK
Former ID
DNC005716
Drug Name
6-Pyridin-3-yl-naphthalen-2-ol
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527801]
Formula
C15H11NO
Canonical SMILES
C1=CC(=CN=C1)C2=CC3=C(C=C2)C=C(C=C3)O
InChI
1S/C15H11NO/c17-15-6-5-11-8-12(3-4-13(11)9-15)14-2-1-7-16-10-14/h1-10,17H
InChIKey
MDXMZUQFVFTPDO-UHFFFAOYSA-N
PubChem Compound ID
11514074
Target and Pathway
Target(s) Cytochrome P450 11B1, mitochondrial Target Info Inhibitor [527801]
17 alpha-hydroxylase-C17, 20-lyase Target Info Inhibitor [527801]
BioCyc Pathway Superpathway of steroid hormone biosynthesis
Glucocorticoid biosynthesis
Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
Androgen biosynthesis
KEGG Pathway Steroid hormone biosynthesis
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
Metabolic pathways
Ovarian steroidogenesis
Prolactin signaling pathway
PathWhiz Pathway SteroidogenesisPW000045:Androgen and Estrogen Metabolism
Steroidogenesis
Reactome Glucocorticoid biosynthesis
Endogenous sterolsR-HSA-193048:Androgen biosynthesis
Endogenous sterols
WikiPathways Metapathway biotransformation
Oxidation by Cytochrome P450
Metabolism of steroid hormones and vitamin D
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
Steroid Biosynthesis
Glucocorticoid & Mineralcorticoid Metabolism
Prostate Cancer
Phase 1 - Functionalization of compounds
References
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Ref 527801J Med Chem. 2005 Oct 20;48(21):6632-42.Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.